Samsung BioLogics has announced on the 17th that it has been included in the Dow Jones Sustainability Indices World for four consecutive years.
The Dow Jones Sustainability Indices World is a global ESG (Environmental, Social, and Governance) representative evaluation indicator announced by S&P Global in the United States. It is comprised of the top 10% of corporations in economic performance and ESG performance among more than 2,500 listed companies with the highest market capitalization worldwide.
Since 2021, Samsung BioLogics has been recognized for its ESG management achievements by being included in the World Index for four consecutive years.
According to the company, especially in the Environmental institutional sector, they were recognized for their efforts to achieve net zero by raising the reduction targets for Scope 3 emissions occurring throughout the entire value chain, including suppliers and logistics, and have obtained the highest rating, placing them in the top 1% within the life sciences service sector.
Samsung BioLogics declared its net zero target for 2050 and announced a roadmap in November 2022. Since then, it has been reducing operational and manufacturing energy annually. The company has made achievements in improving infrastructure to build eco-friendly establishments, such as using solar energy and purchasing renewable energy. They are expanding their participation in global climate crisis response initiatives, including risk and opportunity analysis through the Task Force on Climate-related Financial Disclosures (TCFD) report and participation in the Sustainable Market Initiatives (SMI), while also establishing management strategies based on natural capital (TNFD) in areas such as water resources management, biodiversity conservation, and pollution and hazardous substance management.
In the Social institutional sector, the company became the first domestic Contract Development and Manufacturing Organization (CDMO) to join the Pharmaceutical Supply Chain Initiative (PSCI). As a result, the company is strengthening human rights management by conducting internal human rights impact assessments to identify potential risks according to the 'principles for responsible supply chain management' of PSCI and the European Sustainability Reporting Standards (ESRS).
In the Governance institutional sector and Economic institutional sector, the company is enhancing the independence of the board of directors and management transparency by introducing a senior outside director system and identifying improvement tasks to enhance the efficiency of board operations. The company explained that it is continuously working to advance its risk management system in accordance with expanding global ESG assessment standards.
John Lim, president of Samsung BioLogics, said, "Samsung BioLogics being included in the DJSI World Index for four consecutive years shows that the company’s sustainable management is recognized globally," adding, "We will continue to take the lead in spreading efforts toward sustainable management throughout the pharmaceutical and biopharmaceutical industry."